Vor Biopharma Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	169.87	396.49	81.95	31.36	57.71	119.8
Short-Term Investments	321.65	58.72	9.98	105.82	172.54	87.67
Cash & Short-Term Investments	491.53	455.21	91.93	137.18	230.25	207.47
Cash Growth	718.73%	395.19%	-32.99%	-40.42%	10.98%	323.35%
Other Current Assets	9.42	3.07	6.99	3.63	6.71	6.93
Total Current Assets	500.78	458.11	96.51	140.8	236.95	214.4
Net Property, Plant & Equipment	3.39	3.47	41.59	50.1	57.08	22.52
Other Long-Term Assets	2.58	2.55	4.8	7.23	5.34	5.67
Total Assets	506.75	464.13	142.89	198.13	299.37	242.59
Accounts Payable	1.04	5.13	1.51	0.82	1.77	1.55
Accrued Expenses	14.73	19.76	12.89	10.88	7.89	6.34
Current Portion of Leases	0.31	0.28	4.22	3.83	3.27	1.84
Other Current Liabilities	-	-	-	0.05	0.19	0.43
Total Current Liabilities	16.08	25.17	18.61	15.57	13.12	10.15
Long-Term Leases	2.63	2.72	27.62	31.83	35.64	16.17
Other Long-Term Liabilities	638.46	600.55	-	-	-	-
Total Long-Term Liabilities	641.09	603.27	27.62	31.83	35.64	16.17
Total Liabilities	657.17	628.44	46.23	47.4	48.76	26.33
Common Stock	0.02	0.02	0.01	0.01	0.01	0
Additional Paid-in Capital	1,223	988.6	553.62	490.87	473.59	346.38
Accumulated Other Comprehensive Income	-0.71	0.04	0.02	-0.08	-0.77	-
Retained Earnings	-1,373	-1,153	-456.99	-340.08	-222.22	-130.12
Total Common Shareholders' Equity	-150.42	-164.31	96.66	150.72	250.61	216.26
Shareholders' Equity	-150.42	-164.31	96.66	150.72	250.61	216.26
Total Liabilities & Equity	506.75	464.13	142.89	198.13	299.37	242.59
Total Debt	2.94	3	31.83	35.66	38.91	18.01
Net Cash (Debt)	488.59	452.21	60.1	101.52	191.33	189.46
Net Cash Growth	8.04%	652.48%	-40.80%	-46.94%	0.99%	516.86%
Net Cash Per Share	25.63	45.81	17.49	30.22	96.75	113.33
Book Value	-150.42	-164.31	96.66	150.72	250.61	216.26
Book Value Per Share	-7.89	-16.64	28.14	44.86	126.72	129.37
Tangible Book Value	-150.42	-164.31	96.66	150.72	250.61	216.26
Tangible Book Value Per Share	-7.89	-16.64	28.14	44.86	126.72	129.37

SEC Filings: 10-K · 10-Q